TXMD - TherapeuticsMD quarterly net loss widens 24% on bottom line miss

TherapeuticsMD (NASDAQ:TXMD) saw its Q1 2022 net loss widen 24% to $49M (-$5.69 basic and diluted share) compared to the prior-year period weighed down by a $8.4M loss on extinguishment of debt The net loss was a miss while revenue of ~$19.3M, around a 3% year-over-year-decline, was a beat. TherapeuticsMD (TXMD) also said it was hurt in the quarter by manufacturing issues related to its Annovera birth control ring, its top-selling product. Operating expenses of $40.7M was a ~9% drop from Q1 2021. See why Seeking Alpha contributor Biologics says that TherapeuticsMD (TXMD) isdue for a potential turnaround following the sale of its vitaCare business.

For further details see:

TherapeuticsMD quarterly net loss widens 24% on bottom line miss